Overview

Shift Labs was a Seattle-based medical device startup founded in 2012 by Beth Kolko and Koji Intlekofer. The company's flagship product, DripAssist, was a $225 IV drip rate monitor designed to bring basic infusion safety to healthcare settings where $5,000–$15,000 infusion pumps were impractical or unavailable. Shift Labs participated in Y Combinator's Winter 2015 batch and spent the following seven years building distribution across home care, military, and global health channels, earning FDA clearance, CE marking, and a string of industry awards along the way.

The company's core thesis — that incumbents deliberately avoided low-margin devices, leaving a real clinical gap — was correct. But being correct about the gap did not resolve the underlying economics: selling $225 devices at scale requires either very high volume or a radically lean distribution model, and Shift Labs achieved neither before its capital ran thin.

Shift Labs was ultimately acquired, with the acquirer undisclosed. The July 2020 licensing deal granting Hometa exclusive Americas distribution rights signaled that independent scaling had stalled. Founder Beth Kolko transitioned to venture capital roles beginning in 2019, and her biography references approximately ten years as CEO — consistent with a 2012–2022 operational window. The product continues to exist; the independent company did not.

Founding Story

Beth Kolko came to medical device entrepreneurship through an unusual path. A professor of Human Centered Design and Engineering at the University of Washington,^[1] her academic work focused on technology in low-resource settings — the kind of environments where clinical infrastructure is sparse and the gap between what patients need and what they can access is widest. That research lens shaped the founding insight behind Shift Labs: the medical device industry was not failing to serve low-resource settings by accident. It was doing so by design.

Kolko articulated this directly in a 2015 TechCrunch interview, recounting a conversation with a medical device executive: "I once had a VP of a medical device company who took me aside and said, 'We could make simpler and cheaper devices, but then our revenue wouldn't support our sales force.'"^[2] The incumbent business model — high-margin devices sold through expensive direct sales forces — structurally excluded the lower end of the market. Kolko saw that as an opportunity.

Shift Labs was founded in 2012 in Seattle.^[3] The original co-founder departed in 2013 due to family issues,^[4] a meaningful early disruption — though no public record describes what that person contributed or what was lost in the transition. Koji Intlekofer subsequently joined as co-founder and CTO.^[5] No public record describes how Kolko and Intlekofer met or what Intlekofer's background was prior to Shift Labs.

The company's early framing was deliberately ambitious: Shift Labs would be "the Nest of medical devices."^[6] The analogy was to Nest's achievement of bringing consumer-grade simplicity and design quality to a commodity hardware category — applied here to clinical hardware. It was a compelling positioning, though as later events would show, the analogy had limits. Nest sold premium hardware at premium margins into a mass consumer market. Shift Labs would be selling low-margin clinical hardware into fragmented, grant-dependent channels.